For all investor queries, please contact info@vasomune.com.
Latest News
Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors
Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors Industry Leader Joins Vasomune’s Board of Directors as the Company Transitions to Clinical Development of AV-001
March 24, 2020
No Comments
The COVID-19 Coronavirus Leads to Acute Respiratory Distress Syndrome (ARDS)
An article in USA Today describes certain risks associated with contraction of the COVID-19 coronavirus, specifically the major cause of lethality being Acute Respiratory Distress
March 20, 2020
No Comments
Vasomune’s Lead Investigational Medication is Connected to the Fight Against Coronavirus
Coronavirus (COVID-19) kills by inducing Acute Respiratory Distress Syndrome (ARDS). According to a recent article in The Lancet, 12 out of 41 (29%) COVID-19 patients
February 26, 2020
No Comments
Vasomune Therapeutics is at the 38th J.P. Morgan Healthcare Conference
Vasomune Therapeutics is currently attending the 38TH ANNUAL JPM HEALTHCARE CONFERENCE, San Francisco, California
January 15, 2020
No Comments